Compare Matson Inc (MATX) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs Novartis AG — how do they compare? Matson Inc trades at $214.74 (market cap $6.11B), while Novartis AG trades at $154.71 (market cap $295.37B). The key difference: Novartis AG is far larger — about 48.3× Matson Inc's market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| MATX | NVS | |
|---|---|---|
Market Cap | $6.11B | $295.37B |
Sector | Technology | Health |
52-Week High | $223.55 | $168.62 |
52-Week Low | $88.05 | $119.31 |
Enterprise Value | $6.71B | $336.69B |
Dividend Yield | 0.74% | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $214.52, up 2.8% today, with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with consistent earnings beats, a 13.41% net margin, and robust cash flow generation. Recent Q2 2026 results exceeded expectations with EPS of $4.27 versus $3.79 estimate, driving positive analyst sentiment.
Outlook remains positive with 27% upside to consensus target of $265. Key risks include shipping industry cyclicality and global trade volatility. The combination of strong earnings momentum, attractive valuation at 13.79 P/E, and institutional support supports a constructive investment case for the stock.
Novartis (NVS) trades at $152.41, down 2.79% today, with technical indicators showing neutral momentum near key support at $152. The company reported strong Q2 2026 earnings that beat expectations, driven by oncology drug performance, while maintaining a robust 22.5% net margin and $56.7B in revenue. Recent institutional buying activity and a predominantly Hold analyst consensus reflect cautious optimism amid patent expiration headwinds.
The outlook balances strong fundamentals and pipeline progress against generic competition risks. Investment appeal lies in dividend stability and new drug growth, though Entresto sales decline and U.S. pricing pressures require monitoring. The stock presents a defensive opportunity with moderate upside potential if newer therapies continue outperforming.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
